New approaches in the management of multiple sclerosis

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 343-366

  Barten, Laurie J ^a   Allington, Douglas R ^a   Procacci, Kendra A ^b   Rivey, Michael P ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b The University of Montana School of Pharmacy   (United States)

Author keywords

Monoclonal antibody; Multiple sclerosis; Phase II trials; Phase III trials; Progressive multifocal leukoencephalopathy

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BACLOFEN; BETA INTERFERON; BETA1A INTERFERON; CANNABINOID; CLADRIBINE; DACLIZUMAB; DALFAMPRIDINE; ESTRIOL; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; LAQUINIMOD; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MODAFINIL; NATALIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; STEROID; TERIFLUNOMIDE; TIZANIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ALLERGIC ENCEPHALOMYELITIS; ASTHENIA; BACKACHE; BALANCE DISORDER; BEDTIME DOSAGE; BINDING AFFINITY; BINDING SITE; BRADYCARDIA; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FALLING; FATIGUE; FIRST DEGREE ATRIOVENTRICULAR BLOCK; FLUSHING; HEADACHE; HEALTH SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOGENESIS; INFECTION; INSOMNIA; LEIOMYOMA; LEUKEMIA; LEUKOPENIA; LIVER FUNCTION TEST; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MENOMETRORRHAGIA; MENTAL DISEASE; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PARESTHESIA; PREVALENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; RASH; RETINA MACULA EDEMA; REVIEW; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SEX RATIO; SIDE EFFECT; SINUSITIS; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS BLEEDING; VIRUS INFECTION; WEAKNESS; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECURRENT DISEASE;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RECURRENCE;

EID: 79952494803     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S9331     Document Type: Review

References (129)

1. Pithadia A, Jain S, Navale A. Pathogenesis and treatment of multiple sclerosis (MS). Int J Neurol. 2009;10(2):1-20.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
3. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313): 1221-1231.
4. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann Neurol. 2005;58(6):840-846.
5. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-127.
6. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14(9):1157-1174.
7. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61(5):602-611.
8. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009; 15(10):1175-1182.
9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576-1582.
10. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Champs Study Group. N Engl J Med. 2000;343(13):898-904.
11. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7): 1242-1249.
12. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700): 1503-1511.
13. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3 year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397.
14. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon β-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5):678-684.
15. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52(1):61-76.
16. Douglass LH, Jorgensen CL. Pregnancy and multiple sclerosis. Am J Obstet Gynecol. 1948;55(2):332-336.
17. Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010; 74 Suppl 3: S8-S15.
18. Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology. 2010;74 Suppl 3:S24-S35.
19. Mangano K, Nicoletti A, Patti F, et al. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin Exp Immunol. 2009;159(2):159-168.
20. Bettelli E, Pagany M, Weiner HL, et al. Myelin oligodendrocyte glycoprotein-specif ic T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003;197(9): 1073-1081.
21. Zamvil S, Nelson P, Trotter J, et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature. 1985;317(6035):355-358.
22. Gold R, Linington C, Lassmann H. Understanding the pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129(Pt 8):1953-1971.
23. van der Walt A, Butzkueven H, Kolbe S, et al. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther. 2010;126(1):82-93.
24. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61(4):288-299.
25. Peltonen L. Old suspects found guilty-the first genome profile of multiple sclerosis. N Engl J Med. 2007;357(9):927-929.
26. The International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851-862.
27. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008;9(7):516-526.
28. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci. 2002;25:491-505.
29. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005;23:683-747.
30. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-955.
31. Stuve O. Knowns and unknowns in the future of multiple sclerosis treatment. J Neurol Sci. 2009;287 Suppl 1:S30-S36.
32. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6(12):1182-1190.
33. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
34. Steinman L. A molecular trio in relapse and remission in multiple sclerosis. Nat Rev Immunol. 2009;9(6):440-447.
35. + T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J Immunol. 2008;181(11):7480-7488.
36. Bettelli E, Oukka M, Kuchroo VK. TH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345-350.
37. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2006;8(1):74-83.
38. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelination disease. Science. 2001;294(5547):1731-1735.
39. Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S. Up-regulation of osteopontin and αβ-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol. 2005;31(3): 292-303.
40. Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008; 451(7182):1076-1081.
41. Ousman SS, Tomooka BH, van Noort JM, et al. Protective and therapeutic role for αβ-crystallin in autoimmune demyelination. Nature. 2007;448(7152):474-479.
42. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol. 2001;21(2):81-92.
43. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998; 338(5):278-285.
44. Butovsky O, Landa G, Kunis G, et al. Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis. J Clin Invest. 2006;116(4):905-915.
45. Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG. Co-localization of sodium channels Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain. 2004;127(Pt 2): 294-303.
46. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59(3):478-489.
47. Ouardouz M, Coderre E, Zamponi GW, et al. Glutamate receptors on myelinated spinal cord axons: II. AMPA and GluR5 receptors. Ann Neurol. 2009;65(2):160-166.
48. Drew PD, Chavis JA, Bhatt R. Sex steroid regulation of microglial cell activation: relevance to multiple sclerosis. Ann N Y Acad Sci. 2003; 1007:329-334.
49. McClain MA, Gatson NN, Powell ND, et al. Pregnancy suppresses experimental autoimmune encephalomyelitis through immunoregulatory cytokine production. J Immunol. 2007;179(12): 8146-8152.
50. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology. 1999;52(6):1230-1238.
51. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor α ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci. 2006;26(25):6823-6833.
52. Zhu WH, Lu CZ, Huang YM, Link H, Xiao BG. A putative mechanism of remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells. Mult Scler. 2007; 13(1): 33-40.
53. Baker AE, Brautigam VM, Watters JJ. Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor β. Endocrinology. 2004;145(11):5021-5032.
54. Offner H. Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. J Neurosci Res. 2004;78(5):603-624.
55. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521-574.
56. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a mutlicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-661.
57. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1996; 39(3):285-294.
58. Randomised double-blind placebo-controlled study of interferon β -1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-1504.
59. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
60. Coyle PK. Disease-modifying agents in multiple sclerosis. Ann Indian Acad Neurol. 2009;12(4):273-282.
61. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-178.
62. Sorensen PS, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol. 2005;12(11):817-827.
63. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
64. National Multiple Sclerosis Society. Update on Tysabri and PML: sponsor and FDA provide information on cases and risks. Available from: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=2308/. Accessed Jun 29 2010.
65. US. Food and Drug Administration. FDA drug safety communication: risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm199872.htm/. Accessed Jun 29 2010.
66. Dangond F. Multiple sclerosis. eMedicine Neurology. 2010. Available from: http://emedicine.medscape.com/article/1146199-print.
67. Miller DH, Leary SM. Primary progressive multiple sclerosis. Lancet Neurol. 2007;6(10):903-912.
68. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmcol Exp Ther. 2003;305(1):70-77.
69. O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009;72(1):73-79.
70. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):402-415.
71. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401.
72. Giovannoni G, Comi G, Cook S, et al. A Placebo-controlled trial of oral cladribine for relapsing multiple sclerosis [phase III]. N Engl J Med. 2010;362(5):416-426.
73. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009; 66(4):460-471.
74. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900.
75. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRImonitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371(9630):2085-2092.
76. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-1472.
77. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
78. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358(7):676-688.
79. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009; 66(4): 483-489.
80. Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J. 2008;15(2):62-68.
81. Salemi G, Callari G, Gammino M, et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol Scand. 2004;110(1):23-26.
82. Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127(Pt 6):1353-1360.
83. Sicotte ML, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estiol. Ann Neurol. 2002;52(4): 421-428.
84. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskul RR. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 2003;171(11):6267-6274.
85. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for non-malignant disease. JAMA. 2008;299(8):925-936.
86. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805-816.
87. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7): 2364-2372.
88. Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102(7): 2373-2378.
89. Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000;6(5A): 563-575.
90. Fassas A, Passweg JR, Anagnostopoulos A, et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol. 2002;249(8):1088-1097.
91. +selected autologous peripheral blood stem cell transplantation for multiple slcerosis: report of toxicity and treatment results at one year follow-up in 15 patients. Haematologica. 2003;88(3):306-314.
92. Capello E, Saccardi R, Murialdo A, et al. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol Sci. 2005;26 Suppl 4:S200-S203.
93. Xu J, Ji BX, Su L, Dong HQ, Sun XJ, Liu CY. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis. Chin Med J (Engl). 2006;119(22): 1851-1855.
94. Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology. 2001;57(1):62-68.
95. Sorensen PS, Mellgren SI, Svenningsson A, et al. NORdic trial of oral methylprednisoloine as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol. 2009;8(6):519-529.
96. Ravnborg M, Sorensen PS, Andersson M, et al. Methylprednisolone in combination with interferon β-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol. 2010;9(7):672-680.
97. Cohen JA, Imrey PB, Calabresi PA, et al. Results of Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6): 535-541.
98. Havrdova E, Zivadinov R, Krasensky J, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler. 2009;15(8):965-976.
99. Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806-812.
100. Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. A double blind, placebo-controlled, phase II, add-on study of cyclophosamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci. 2004;223(1):69-71.
101. Correale J, Rush C, Amengual A, Goicochea MT. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-β. J Neuroimmunol. 2005;162(1-2):173-183.
102. Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immune-suppression in very active, relapsing remitting multiple sclerosis. J Neurol. 2006;253(9):1160-1164.
103. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299-308.
104. Schapiro RT. Managing symptoms of multiple sclerosis. Neurol Clin. 2005;23(1):177-187, vii.
105. Loss of mobility found to impact quality of life and emotional and financial health of most people living with multiple sclerosis. National Multiple Sclerosis Society [news release on the Internet]. New York: National Multiple Sclerosis Society. March 2008, 25.Available from: http://www.nationalmssociety.org/news/news-detail/index. aspx?nid=199. Accessed Jun 1 2010.
106. Bainbridge JL, Corboy JR. Multiple sclerosis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York (NY): McGraw-Hill; 2008:913.
107. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006;111(1):224-259.
108. Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment of multiple sclerosis. Ann Pharmacother. 2008;42(10):1458-1465.
109. Goodman AD, Brown TR, Krupp LB. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732-738.
110. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71(15):1134-1141.
111. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, doseranging study. Mult Scler. 2007;13(3):357-368.
112. Acorda Therapeutics. Acorda Therapeutics announces positive data from second Phase 3 study of fampridine-SR on walking ability in people with multiple sclerosis. Available from: http://phoenix.corporate-ir.net/phoenix.zhtml?c=194451&p=irolnewsArticle&ID=1160986&highlight. Accessed Jun 1 2010.
113. Acorda Therapeutics, Inc. Fampridine-SR Advisory Committee briefing document. Fampridine-SR tablets for improvement in walking ability in patients with multiple sclerosis. Peripheral and Central Nervous System Drugs Advisory Committee Meeting; 2009 Oct 14; NDA22-250. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM185664.pdf. Accessed Jun 20 2010.
114. Goodman AD, Brown T, Krupp L, et al. Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis [abstract]. Mult Scler. 2009; 15 Suppl 2:S13.
115. Goodman AD, Brown TR, Edwards KR, et al. Interim analysis of openlabel extension studies of dalfampridine extended release tablets in patients with multiple sclerosis [Abstract S01.008]. Proceedings of the American Academy of Neurology 2010 Annual Meeting; 2010 Apr 13; Toronto, Canada. Abstract available from: http://www.abstracts2view. com/aan/view.php?nu=AAN10 L_S01.008. Accessed Jun 8 2010.
116. Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology. 1997;48(4):817-821.
117. Sanofi-Aventis. Efficacy, safety, and tolerability of nerispirdine in patients with multiple sclerosis. Last updated 2010 Mar 22. ClinicalTrials. gov Web site. Available from: http://clinicaltrials.gov/ct2/show/NCT00811 902. Accessed Apr 9 2010.
118. Smith C, Kongsamut S, Wang H, Ji J, Kang J, Rampe D. In vitro electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivative. Clin Exp Pharmacol Physiol. 2009;36(11):1104-1109.
119. Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4): 645-650.
120. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother. 2010;44(6): 1098-1103.
121. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005;64(7):1139-1143.
122. ® for treating spasticity, or tightness, in upper limbs. National Multiple Sclerosis Society [news release on the Internet]. New York: National Multiple Sclerosis Society. 2010 Mar 12. Available from: http://www.nationalmssociety.org/news/news-detail/ index.aspx?nid=2875. Accessed May 17 2010.
123. Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag. 2010;6:59-63.
124. Christodoulou C, Melville P, Scherl WF, Macallister WS, Elkins LE, Krupp LB. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci. 2006;245(1-2):127-136
125. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008;35(4):476-481.
126. Morrow SA, Kaushik T, Zarevics P, et al. The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(7):1095-1102.
127. Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715-723.
128. Kleinschnitz C, MEuth SG, Kieseier BC, Wiendl H. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets. 2007;7(1):35-63.
129. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008;29(11):558-565.